Laserfiche’s Taylor Grosso Honored as 2026 CRN® Channel Chief

 (BUSINESS WIRE) -- Laserfiche — the leading SaaS provider of intelligent content management — announced today that CRN® — a brand of The Channel Company — has selected Taylor Grosso, senior director, channel, Americas, as a 2026 CRN® Channel Chief. This annual recognition celebrates IT vendor and distribution executives who are shaping channel strategy and driving innovation and partnership across the industry.

Grosso oversees Laserfiche’s Americas channel sales team, including the U.S., Canada, and Latin America, focusing on empowering Laserfiche Solution Providers to stay competitive as the market evolves. As more organizations seek out AI-powered tools to enhance productivity, Grosso prepares partners with the resources they need to quickly learn and sell Laserfiche’s industry-leading AI-powered document management solutions. By working closely with partners on building targeted business plans, Grosso and his team enable faster customer adoption of AI while driving revenue growth.

“Over the past year, we’ve seen the transformative potential of AI in solving organizations’ information management challenges,” said Grosso. “My goal — and the goal of the entire Laserfiche channel team — is to enable partners to succeed in this moment with the latest Laserfiche tools that deliver on the promise of AI through tangible and profitable solutions.”

“Taylor is an exceptional channel leader who prioritizes trust, relationship-building and mutual success with the channel,” said Josep Domingot, vice president of sales at Laserfiche. “This recognition by CRN is a testament to the strength of the Laserfiche Solution Provider Program and continuous innovation of the Laserfiche product.”

The annual CRN Channel Chiefs list spotlights the most influential leaders across the IT channel, celebrating those who champion collaboration, drive innovation and empower their partners and customers to achieve shared success.

“Leaders recognized as CRN Channel Chiefs this year have demonstrated unwavering commitment to their partners and the broader IT channel. Their vision, passion and drive for innovation continue to shape the future of our industry. We are proud to celebrate their achievements and the positive impact they make every day,” said Jennifer Follett, vice president, U.S. content, executive editor, CRN.

CRN’s 2026 Channel Chiefs list will be featured on CRN.com beginning Feb. 2 at www.CRN.com/ChannelChiefs.

About Laserfiche

Laserfiche is a leading enterprise platform that helps organizations digitally transform operations and manage their content with AI-powered solutions. Through scalable workflows, customizable forms, no-code templates and AI-enabled capabilities, the Laserfiche® document management platform accelerates how business gets done. Trusted by organizations of all sizes—from startups to Fortune 500 enterprises—Laserfiche empowers teams to boost productivity, foster collaboration, and deliver a superior customer experience at scale. Headquartered in Long Beach, California, Laserfiche operates globally, with offices across North America, Europe, and Asia.

Connect with Laserfiche: Laserfiche Blog | X | LinkedIn | Facebook

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260202625964/en/

Permalink

https://www.aetoswire.com/en/news/0202202652935

Contacts

Laserfiche Contact:

Linda Domingo

Communications Director, Laserfiche

Linda.domingo@laserfiche.com

562-988-1688 ext. 234

Umm Al Qura for Development & Construction Company launches unified digital platform for developers in Masar Destination

 Riyadh, Saudi Arabia -

During its participation in the Future Real Estate Forum 2026.

 

Umm Al Qura for Development & Construction Company, the owner, developer, and operator of Masar Destination, announced the launch of a unified digital platform for property ownership within the destination through approved developers.

The new digital platform provides accurate and up-to-date information in both Arabic and English about all approved developers within Masar destination, thus enhancing transparency and establishing high levels of regulation within an integrated urban system.

This initiative, which reflects the Company’s responsible approach to urban development and its commitment to preserving the unique character of place and enhancing quality of life, was launched as part of the company’s participation in Future Real Estate Forum 2026, the Kingdom’s premier event in this industry, which features broad international participation including representatives from more than 120 countries and over 300 global speakers.

Commenting on the initiative, Mr. Yasser Abuateek, Chief Executive Officer of Umm Al Qura for Development & Construction Company, said, “The launch of the unified digital ownership platform at Masar is a strategic step toward enhancing transparency and innovation in the real estate sector. It highlights our commitment to providing an integrated urban experience that supports the goals of Saudi Vision 2030 and contributes to positioning Makkah at the forefront of digital transformation. It also strengthens confidence in the real estate market by offering diverse options that meet residents’ needs within a modern and sustainable urban environment.”

Spanning over 1.2 million square meters, Masar Destination is the largest urban project in Makkah. Its portfolio, which spans hotels, residential and hotel apartments, and integrated commercial and medical facilities, aligns with the Kingdom’s vision for advanced urban environments that serve both visitors and residents.

The project has recently signed development agreements with a number of developers and investment funds, with total investment exceeding SAR 63 billion, including acquisition and infrastructure costs, reinforcing its position as one of the Kingdom’s most prominent investment destinations.

To learn more about the platform, click here: https://www.masardestination.com.sa/en/developers

Permalink

https://www.aetoswire.com/en/news/2022026529044

Contacts

Khaled Karanouh

+966 507700821

khaledk@prarabia.me

Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission

 ZUG, Switzerland - Monday, 02. February 2026 AETOSWire 

The United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults

RelabotulinumtoxinA is designed to optimize molecule integrity to deliver fast onset of action as early as Day 1 and sustained results for six months for frown lines and crow’s feet and has been approved in over 20 markets, including in the European Union1-3

 

(BUSINESS WIRE)--Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults. Galderma has worked closely with the U.S. FDA to implement adjustments to its manufacturing process. Galderma is committed to using its expertise and heritage in the neuromodulator space to develop next-generation aesthetic solutions that address evolving needs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260201157212/en/

 

“We pioneered the development of RelabotulinumtoxinA to address the growing demand for faster-acting and longer-lasting anti-wrinkle solutions. We’re excited about the potential to bring this innovative neuromodulator to the U.S., offering advanced performance and ease of use and building on our portfolio of neuromodulators that meets the full spectrum of injector and patient needs.”

 

BALDO SCASSELLATI SFORZOLINI, M.D., PH.D.

GLOBAL HEAD OF R&D

GALDERMA

 

The filing is based on data from the robust, large-scale READY (REelabotulinumtoxin Aesthetic Development StudY) clinical trial program, which is composed of four phase III trials, enrolling more than 1,900 participants.1-4 Results demonstrated that RelabotulinumtoxinA delivered a fast onset of action as early as Day 1 and sustained results for six months for both frown lines and crow’s feet.1,2

RelabotulinumtoxinA (Relfydess™) has been approved in over 20 markets for the treatment of frown lines and crow’s feet, including in the European Union, the United Kingdom, Asia, and Australia. Regulatory applications are continuing to be submitted and assessed by additional authorities globally.

Galderma offers a range of neuromodulator solutions aiming to address every single injector and patient need, and has the heritage, expertise and capability needed to continue bringing this advanced solution to patients and healthcare professionals globally. Today, Galderma is well positioned to be the leader in all aspects of Injectable Aesthetics, having the in-house capabilities to discover, research, develop, manufacture, and market best-in-class products.

About RelabotulinumtoxinA

Pioneered by Galderma, RelabotulinumtoxinA is the first and only ready-to-use liquid neuromodulator manufactured with PEARL™ Technology, which is designed to preserve molecule integrity to deliver fast onset of action as early as Day 1 and sustained results for six months for glabellar lines and lateral canthal lines, giving patients a natural, revitalized look in a refined and well-tolerated formulation.1-5 RelabotulinumtoxinA is optimized for simple volumetric dosing, without reconstitution, to increase ease-of-use and help ensure consistent dose/volume every time.6,7 It was entirely created and manufactured by Galderma to expand its neuromodulator portfolio as part of the broadest Injectable Aesthetics portfolio on the market. RelabotulinumtoxinA has received a marketing authorization in numerous markets and is an investigational drug product in the U.S. Authorization conditions may vary internationally.

About Galderma

Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References

Shridharani SM, et al. Efficacy and safety of RelabotulinumtoxinA, a new ready-to-use liquid formulation botulinum toxin: Results from the READY-1 double-blind, randomized, placebo-controlled phase 3 trial in glabellar lines. Aesthet Surg J. 2024;44(12):1330-1340. doi: 10.1093/asj/sjae131.

Ablon G, et al. Treatment of lateral canthal lines with RelabotulinumtoxinA, an investigational liquid botulinum toxin: clinical efficacy and safety results from the READY-2 phase 3 trial. Toxicon. 2024;237(1):107353. doi: 10.1026/j.toxicon.2024.107353.

Relfydess®. EU Summary of Product Characteristics.

Galderma. Data on file. Clinical Study Report for Protocol 43QM1902: READY-3. Galderma Laboratories; 2021

Galderma. Data on file. Clinical Study Report for Protocol 43AM1903: READY-4. Galderma Laboratories; 2021

Sundberg AL and Stahl U. Relabotulinum toxin - a novel, high purity BoNT-A1 in liquid formulation. Presented at TOXINS; January 16-17, 2021; virtual meeting.

Do M, et al. Purification process of a complex-free highly purified botulinum neurotoxin type A1 (BoNT-A1) - relabotulinumtoxinA. Presented at TOXINS; July 27-30, 2022; Louisiana, United States.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260201157212/en/

Permalink

https://www.aetoswire.com/en/news/2022026529022

Contacts

For further information:

Christian Marcoux, M.Sc.

Chief Communications Officer

christian.marcoux@galderma.com

+41 76 315 26 50

Richard Harbinson

Corporate Communications Director

richard.harbinson@galderma.com

+41 76 210 60 62

Céline Buguet

Franchises and R&D Communications Director

celine.buguet@galderma.com

+41 76 249 90 87

Emil Ivanov

Head of Strategy, Investor Relations, and ESG

emil.ivanov@galderma.com

+41 21 642 78 12

Jessica Cohen

Investor Relations and Strategy Director

jessica.cohen@galderma.com

+41 21 642 76 43

Un moment culturel fédérateur pour le monde arabe : « Qatar SoundBeat », initiative du Media City Qatar, continue de toucher des millions de personnes, bien au-delà du plus grand événement footballistique régional

 

Un moment culturel fédérateur pour le monde arabe : « Qatar SoundBeat », initiative du Media City Qatar, continue de toucher des millions de personnes, bien au-delà du plus grand événement footballistique régional

 

Pour la fête nationale du Qatar, lors de la finale de la Coupe Arabe de la FIFA, Qatar 2025™ (FIFA Arab Cup Qatar 2025™) au stade de Lusail, Media City Qatar a marqué un jalon culturel en dévoilant « Nabd Qatar », pièce maîtresse de sa campagne « Qatar SoundBeat ». La première s'est déroulée en présence des dirigeants nationaux, de responsables gouvernementaux, de dignitaires de la région et de supporters de football, unissant les spectateurs venus de toute la région MENA autour d'un moment de partage célébrant l'identité arabe, la créativité et l'expression culturelle sur l'un des stades les plus emblématiques de la région.

Révélée à l’origine comme un spectacle de sons et de lumières, « Nabd Qatar » (Le pouls du Qatar), a depuis pris une dimension plus vaste, pris une dimension plus vaste, séduisant des publics régionaux et internationaux avec plus d’un million de vues sur les réseaux sociaux. Elle est désormais diffusée sur YouTube, Spotify et Anghami.

Conçue et composée par le musicien de renommée régionale Omar Rahbany et produite par Rahbani 3.0., société agréée de Media City Qatar, l’œuvre a métamorphosé le stade de Lusail en une toile vivante de sons et de lumières. Interprété par l’Orchestre Philharmonique du Qatar, l’arrangement met en vedette 68 musiciens et 30 instruments, mêlant les structures symphoniques occidentales à l’instrumentation arabe traditionnelle.

« Nabd Qatar » s’inspire des sons qui font l’âme du pays, familiers dans tout le GCC. L’œuvre évoque les Chants de danse de l’épée Ardha ; paroles traditionnelles écrites par SEM Salah bin Ghanem Al Ali, passant par le bourdonnement des dunes du désert, le murmure du vent et l’appel d’un faucon, et évoquant le galop d’un cheval arabe, le flottement du drapeau national et la cadence d’un battement de cœur.

Les paroles, rédigées par Abdullah Khaled Abdulquddus, s’appuient sur la campagne « Qatar ArtBeat », une initiative établissant un record mondial Guinness pour la Journée nationale du Qatar 2024, où des milliers de contributions ont été recueillies auprès du public. Le résultat est un clip musical exclusif réalisé par le réalisateur de renom Karim Rahbani, qui parle littéralement avec la voix du peuple, diffusé sur les réseaux sociaux pour toucher les audiences à l’échelle mondiale.

S.E. le Cheikh Dr Abdulla bin Ali Al Thani, président de Media City Qatar, a déclaré : « L’initiative ‘Qatar SoundBeat’ transforme les sons authentiques de notre nation en une œuvre unique, révélée lors de la finale de la Coupe Arabe de la FIFA, Qatar 2025™, devant plus de 88 000 spectateurs venus du monde arabe. Media City Qatar a profité de ce moment pour envoyer un message clair à la communauté créative de la région : l’avenir des médias arabes se façonne ici. Elle appelle tous les créateurs de notre région à considérer le Qatar comme un endroit où de nouvelles idées peuvent se développer et s’épanouir. C’est l’esprit même de notre stratégie : ‘Where Next is Made’ (Là où se construit l'avenir/le prochain chapitre). »

Omar Rahbany, compositeur de « Nabd Qatar » et cofondateur de Rahbani 3.0, a ajouté : « Media City Qatar nous a confié la mission de créer une œuvre musicale à la hauteur de l’histoire d’une nation. Chaque détail a été conçu avec intention, depuis les éléments phonétiques qui évoquent la cadence d’un battement de cœur, aux efforts collectifs des dizaines de techniciens de diverses disciplines ayant permis de donner vie à la composition. »

Pour sa part, le Dr Nasser Sahim, directeur exécutif adjoint de l’Orchestre Philharmonique a déclaré : « Interpréter ‘Nabd Qatar’ a été un honneur pour l’Orchestre Philharmonique du Qatar. Une œuvre de cette envergure exigeait précision, unité et une compréhension musicale approfondie. Nos musiciens l’ont abordée avec un engagement réfléchi envers l’excellence dans chaque note. »

Au-delà de la musique, Media City Qatar (MCQ) continue de renforcer l’écosystème des médias au Qatar, qui héberge désormais plus de 300 entreprises agréées dans les domaines des médias, des jeux, de l’innovation numérique et de la création de contenu.

Le texte du communiqué issu d’une traduction ne doit d’aucune manière être considéré comme officiel. La seule version du communiqué qui fasse foi est celle du communiqué dans sa langue d’origine. La traduction devra toujours être confrontée au texte source, qui fera jurisprudence.

Permalink
https://aetoswire.com/fr/news/QMC28012026F

Contacts

Ysa Chandna
ychandna@webershandwick.com

Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões

 Lisbon, Portugal - Saturday, 31. January 2026 AETOSWire Print 

His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide.

The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and intercultural dialogue.

In his keynote address, President of Portugal said the visit of Sharjah Ruler reflects the historical bonds of friendship between the two countries. He highlighted the shared personal commitment with His Highness to advancing cultural dialogue and understanding between cultures, expressing his belief that future generations will continue to benefit from this intellectual exchange as a fundamental driver of social inclusion.

Addressing His Highness, President de Sousa said:“As we celebrate the 50th anniversary of the diplomatic relationship between the UAE and Portugal this year, I find no better way to mark this occasion than by honouring your enlightened and open personality, and by recognising your valuable contribution to dialogue between cultures, founded on intellectual dedication and shared empathy.”

The President also referred to the long-standing relationship between His Highness and Portugal’s cultural and academic institutions, particularly the University of Coimbra, where the Ruler of Sharjah received an honorary doctorate in 2018 in recognition of his scholarly, literary, cultural, and humanitarian contributions, as well as his research on the Portuguese presence in Asia and the Middle East. He added that this relationship was further strengthened during His Highness’s most recent visit, which included the inauguration of the Centre for Arabic Studies and the Joanina Digital Library.

In his address, Sharjah Ruler expressed his happiness at the honour and its cultural significance, describing it as a meaningful recognition from a nation distinguished by its cultural heritage. He said: “Each time I visit Portugal, I feel as though I am in the presence of history itself, alive and present, the history of relations between this country and the Arab Gulf. Through this warm reception, I see how history can be guided toward a new course of cooperation and constructive progress.”

His Highness added that the honour reflects pride in Arab culture, the cultural vision of the UAE, and Sharjah’s firm conviction that culture is a necessity for human progress. He thanked Portugal for its openness to world cultures and its belief in dialogue between civilisations, stressing that culture is “a bridge we build with others, not merely a legacy we preserve.”

Sharjah Ruler concluded his address by expressing his condolences to the Portuguese Republic following the recent storm that claimed several lives.

The Grand Collar of the Order of Camões, awarded by sovereign decree of the President of Portugal, bears the name of the poet Luís de Camões and is reserved in its highest grade for a limited number of leaders whose cultural influence extends beyond national borders.

The honour recognises the cultural project led by the Ruler of Sharjah over more than five decades, through which knowledge, language, and history have served as enduring bridges for cross-cultural understanding.

Permalink

https://www.aetoswire.com/en/news/3101202652894

Contacts

Hussain Al Mulla

Hussain.AlMulla@SGMB.ae

Galderma Tackles Menopause-related Skin Changes With Global Survey and Clinical Trial Inclusivity

 

• Results from a global survey of over 4,300 women across five continents presented at IMCAS 2026 reveal a knowledge gap on the impact of menopause on the skin, despite women experiencing around three skin changes during menopause¹
• Galderma will also host a symposium delving into the challenges and science behind menopause-related skin changes and aesthetic solutions at the congress
• Galderma is committed to raising awareness of the impact of menopause on the skin, fostering meaningful dialogue between patients and healthcare professionals, and advancing science-backed solutions by incorporating menopausal status into all injectable aesthetics clinical trials

 

(BUSINESS WIRE)--Galderma (SIX: GALD) has unveiled findings from a global survey of peri- and post-menopausal women from nine countries exploring the impact of menopause on the skin at the International Master Course on Aging Science (IMCAS) 2026 World Congress in Paris, France, from January 29-31, 2026. The survey found that over 50% of women learned about the effects of menopause on the skin by going through it themselves, with most finding out about it in their 40s.² However, over 30% would have liked to learn about this in their 30s and over 50% are at best neutral or dissatisfied with their knowledge on the topic.²

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260129610958/en/

To address this knowledge gap, Galderma will leverage its expertise in dermatology to advance awareness, understanding, education, and treatment approaches for menopause-related skin changes. With around 85% of aesthetic patients being female, it is important to understand how these treatments can support women at all stages of life, especially during the complex time of the menopause.³ To help advance this understanding, Galderma has made the pioneering decision to now include menopausal status in its clinical trials to provide critical insights into how its injectable aesthetic treatments can best serve this patient population.

Menopausal women experience a decline in estrogen, which supports many aspects of skin health, with fluctuations starting in the peri-menopausal stage.^4,5 Decreasing estrogen leads to an expedited decline in collagen and elastin, with a 30% reduction in collagen seen within the first five years post-menopause, causing the skin to lose firmness and be more prone to wrinkles.^4-6 It also decreases the hyaluronic acid levels in the skin, which can result in dehydration, dryness, and itchiness.⁴

Often not very well-known and understood, the effects of menopause on the skin are frequently overlooked but can negatively impact wellbeing.^2,7,8 Galderma’s survey found that women agreed or strongly agreed that menopause-related skin changes made them feel less attractive (60%), anxious (57%), less confident (55%), and want to socialize less (46%).¹ Aesthetic treatments can help to address this by targeting the root causes and correcting these skin changes for an enhanced look, and as a result, can boost confidence and positive self-perception.^4,5

“Aesthetic treatments are important tools in addressing and preventing the varied menopause-related skin changes women can experience. Hyaluronic acid treatments can help to correct skin changes through enhanced hydration and contour, whereas biostimulators can help to regenerate skin health from the inside by boosting collagen and elastin to improve firmness and radiance. This survey is an important step forward in understanding the impact of menopause-related skin changes and the role that aesthetic solutions can play for both prevention and treatment.”   DR. DORIS DAY BOARD-CERTIFIED DERMATOLOGIST UNITED STATES

Global findings highlight the unspoken struggles of skin changes during menopause
Galderma’s survey presented as a poster at IMCAS included more than 4,300 peri- and post-menopausal women aged 45-60 from the United States, Brazil, Germany, the United Kingdom, Saudi Arabia, United Arab Emirates, Egypt, China, and Thailand, who have had or would be open to aesthetic treatments.¹ Results showed:

• The women surveyed experienced an average of three skin changes to the face and body since the start of menopause.² The main changes were lines and wrinkles (experienced by 59% of women on the face and 33% on the body), loss of firmness and elasticity (58% on the face and 54% on the body), increased dryness (56% on the face and 58% on the body) and a duller skin tone (40% on the face and 30% on the body).¹
• The overall impact of skin changes on the face and body was rated six out of ten in severity.²
• Of all the treatments or actions to help reduce the effects of menopause – such as cognitive behavioral therapy, exercise changes, food supplements and traditional medicine – aesthetic treatments had the highest level of satisfaction with results.²
• Many women said they would consider aesthetic treatments in the future to help with menopause-related skin changes: 47% would consider anti-wrinkle treatment, 41% hyaluronic acid treatment, 39% hyaluronic acid skin quality treatment, and 30% biostimulators.²
• Currently, women primarily use aesthetics as treatment for menopause related-skin changes (49%) rather than for prevention (26%), likely because many women learned about the impact on the skin when going through the menopause, restricting the window for preventative action.² Yet, over 60% of women would have acted differently if they had known earlier about the impact of menopause on the skin.²

At IMCAS, Galderma will also host a symposium with live demonstrations titled ‘Menopause in the Mirror: Challenges, Science and Aesthetic Solutions’ on Friday, January 30 at 10:30 AM – 12:30 PM CET in Grand Amphi - Level 1. This reinforces Galderma’s focus on community education on menopause-related skin changes, as part of its broader commitment to identifying and addressing real patient needs.

“As the pure-play dermatology category leader, we are committed to driving meaningful change for every skin story. Through this global survey, close collaboration with our network of experts and ensuring that menopausal status is included in all our clinical trials moving forward, we aim to elevate awareness and advance aesthetic solutions, backed by robust evidence, for women navigating this important life stage.”   BILL ANDRIOPOULOS, PH.D. HEAD OF GLOBAL MEDICAL AFFAIRS GALDERMA

Science-backed solutions to help the skin thrive through menopause
Galderma, with its broad injectable aesthetics portfolio, deep expertise in dermatology, and close collaboration with the community, is well positioned to spearhead a drive in awareness around menopause-related skin changes, to ensure it becomes an integral part of patient-healthcare professional conversations and provide effective science-backed solutions.

Galderma’s complimentary portfolio can address the underlying causes of these skin changes. Sculptra^®, the first proven regenerative biostimulator, boosts elastin and collagen across the three layers of the skin, helping to gradually restore volume, firmness, radiance and skin quality, with results lasting for more than two years, and its indication in the European Union was recently expanded for use beyond the face on the body.^9-16 While Galderma’s Restylane^® portfolio of hyaluronic acid treatments, with a formulation that closely mimics the skin’s naturally occurring hyaluronic acid, is designed to help the skin stay hydrated and smooth.^17-23

About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References

1. Fabi G, et al. The potential role of biostimulators/dermal fillers to address menopause-related skin conditions. Poster presented at IMCAS; January 29-31, 2026; Paris, France.
2. Galderma. Data on file. Menopause Patient Survey.
3. Ashley E, Chadha P, and Watson L. Unveiling Gender Disparity: A Closer Look at Speaker Representation at International Aesthetic Medicine Conferences. J Clin Aesthet Dermatol. 2024;17(9):25-27.
4. Viscomi B, Muniz M, Sattler S. Managing Menopausal Skin Changes: A Narrative Review of Skin Quality Changes, Their Aesthetic Impact, and the Actual Role of Hormone Replacement Therapy in Improvement. J Cosmet Dermatol. 2025;24(Suppl 4):e70393. doi: 10.1111/jocd.70393.
5. Lephart ED and Naftolin F. Menopause and the Skin: Old Favorites and New Innovations in Cosmeceuticals for Estrogen-Deficient Skin. Dermatol Ther (Heidelb). 2020;11(1):53-69. doi: 10.1007/s13555-020-00468-7.
6. Thornton MJ. Estrogens and aging skin. Dermatoendocrinol. 2023;5(2):264-270. doi:10.4161/derm.23872/
7. Foulc P, et al. Impact of menopause on the skin…information still insufficient. JEADV. 2024;38(1):e29-e31. doi: 10.1111/jdv.19407.
8. Bravo B, et al. Dermatological Changes during Menopause and HRT: What to Expect? Cosmetics. 2024;11(1);9. doi: 10.3390/cosmetics11010009.
9. Sculptra^®. EU Instructions for Use. 2025. Available online. Accessed January 2026.
10. Waibel J, et al. Bulk RNA-seq Analysis of Poly-L-Lactic Acid (PLLA-SCA) vs Calcium Hydroxyapatite (CaHA-R) Reveals a Novel, Adipocyte Mediated Regenerative Mechanism of Action Unique to PLLA. Poster presented at ASDS 2024 Annual Meeting; October 17-20, 2024; Orlando, Florida, United States.
11. Waibel J, et al. Gene Analysis of Biostimulators: PLLA-SCA Triggers Regenerative Morphogenesis while CaHA-R Induces Inflammation upon Facial Injection. Poster presented at ASDS 2024; October 17-20, 2024; Orlando, Florida, United States.
12. Huth S, et al. Molecular Insights into the effects of PLLA_SCA on Gene Expression and Collagen Synthesis in Human 3D Skin Models Containing Macrophages. J Drugs Dermatol. 2024;23(4):285–288. doi: 10.36849/JDD.7791.
13. Galderma. Data on File (MA-46589).
14. Vleggaar D, et al. Consensus recommendations on the use of injectable poly-L-lactic-acid for facial and nonfacial volumization. J Drugs Dermatol. 2014;13(4 Suppl):s44–s51.
15. Widgegrow J, et al. A randomized, comparative study describing the gene signatures of poly-l-lactic acid (PLLA-SCA) and Calcium Hydroxyapatite (CaHA) in the treatment of nasolabial folds. Poster presented at IMCAS World Congress; February 1-3, 2024. Paris, France.
16. Duracinsky M, et al. Safety of poly-L-lactic acid (New-Fill^®) in the treatment of facial lipoatrophy: a large observational study among HIV-positive patients. BMC Infect Dis. 2014;14(474). doi: 10.1186/1471-2334-14-474.
17. Edsman K, et al. Gel properties of hyaluronic acid dermal fillers. Dermatol Surg. 2012;38:1170–1179. doi: 10.1111/j.1524-4725.2012.02472.x.
18. Galderma. Data on file. MA-58650. Degree of modification of HA fillers.
19. Seo K. Facial volumization with fillers Springer. 2021;29–83. https://doi.org/10.1007/978-981-33-6212-3_2.
20. Kablik J et al. Comparative physical properties of hyaluronic acid dermal fillers. Dermatol Surg. 2009:35S(1):302–312. doi: 10.1111/j.1524-4725.2008.01046.x.
21. Di Gregorio C, Avelar L, Lam S, et al. 25+ years of experience with the Restylane portfolio of injectable HA fillers for facial aesthetic treatment. E-poster presented at AMWC; March 27-29, 2024; Monaco.
22. Solish N, et al. Dynamics of HA fillers formulated to maintain natural facial expression. J Cosmet Dermatol. 2019;18(3): 738-746. doi: 10.1111/jocd.12961.
23. Philipp‐Dormston WG, et al. Perceived naturalness of facial expression after HA filler injection in nasolabial folds and lower face. J Cosmet Dermatol. 2020;19(7):1600-1606. doi: 10.1111/jocd.13205.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260129610958/en/

 

Permalink
https://www.aetoswire.com/en/news/3001202652887

 

Contacts

For further information:

Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50

Richard Harbinson
Corporate Communications Director
richard.harbinson@galderma.com
+41 76 210 60 62

Céline Buguet
Franchises and R&D Communications Director
celine.buguet@galderma.com
+41 76 249 90 87

Emil Ivanov
Head of Strategy, Investor Relations, and ESG
emil.ivanov@galderma.com
+41 21 642 78 12

Jessica Cohen
Investor Relations and Strategy Director
jessica.cohen@galderma.com
+41 21 642 76 43

Convera Appoints Industry Leader Meaghan Riley as Chief Commercial Officer to Scale Commercial Growth and Expand Revenue Opportunities

 Former Google Cloud and SAP executive will build on Convera’s success and leadership in the commercial payments sector

 

(BUSINESS WIRE)--Convera, a global leader in commercial payments, today announces the appointment of Meaghan Riley to Chief Commercial Officer, as the company continues its growth trajectory, expands to new markets, and drives scalable revenue opportunities across geographies and sectors. Prior to Convera, Meaghan was Chief Operating Officer for Google Cloud North America, where she led a major go-to-market transformation and launched high-growth segments.

“Meaghan’s impressive career journey and proven track record brings exceptional experience and unique assets that will strengthen our leadership team at this pivotal moment in Convera’s journey,” said Patrick Gauthier, CEO, Convera. “Meaghan’s leadership will be instrumental in delivering on our commitment to make global business payments simpler and smarter—serving our customers with excellence while building a high performing, aligned organization.”

“As Convera continues to lead the market and deliver next generation commercial payments globally, Meaghan will play a key role in advancing our vision. She brings to Convera the know-how to enhance our market presence and unify our go-to-market (GTM) teams into a powerful, revenue growth engine,” stated Bill McNichols, Convera Chairman of the Board, co-founder and managing partner of Goldfinch partners.

Prior to leading operations for Google Cloud, Meaghan held senior leadership roles at DocuSign and SAP. She has delivered exceptional growth and financial results across industries, having led complex operations in North America, Europe, Asia, and Latin America. Her financial acumen and strong capabilities leading GTM teams will help Convera position itself as a global leader in business payments. She is a passionate advocate for diversity and inclusion, championing programs to foster equity and representation in the workplace.

“I am proud and energized to join this ambitious leadership team as they continue to lead the market,” said Meaghan Riley, newly appointed Chief Commercial Officer, Convera. “Convera’s core values and growth mindset attracted me to join the movement they are leading, and together, I am excited to unlock new revenue opportunities and meet the rapidly growing global customer demand for modern commercial payments.”

Convera Drives Sustainable Growth Across Segments

“We knew 2025 would be an ambitious year for Convera. Like many organizations, we’ve had to navigate through uncertainty, but we’ve responded with resilience in a moment of challenge and complexity. As a result, we’ve made meaningful, measurable accomplishments worthy of celebrating,” said Gauthier.

In 2025, Convera accelerated its transformation. The company delivered record performance, achieving double digit revenue growth and increased total turnover to nearly USD 190B with payments transaction capacity reaching more than 18,000 transactions per hour. The company was recognized for its services by marquis customers across segments, including Identity Digital, IDB Global Federal Credit Union, Betcris, Melecs and Prisma Capital, to name a few.

Convera also invested in future-proofing security and compliance measures by completing its SOC2 certification, in addition to establishing a new strategic collaboration with iPID, a global Know Your Payee (KYP) verification provider, to enhance our payment validation process and comply with the Verification of Payee (VoP) mandate issued by the European Union. Furthermore, Convera successfully deployed AI-powered solutions across the entire organization, to elevate productivity and enable teams in engineering, sales, marketing, and operations to reach new heights of innovation and impact.

About Convera

Convera is a global leader in commercial payments. With an unrivaled regulatory footprint and a financial network spanning more than 140 currencies and 200 countries and territories, Convera is reimaging the future of business payments. We combine tech-led payment solutions with deep expertise in foreign exchange, risk management, and compliance. From small businesses to CFOs and treasurers, we’re helping our customers grow with confidence. Convera makes business payments simple, smart, and secure.

To learn more about Convera, visit https://convera.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260129799440/en/

Permalink

https://www.aetoswire.com/en/news/54407802

Contacts

 

pr@convera.com